Trial · NCT04818086
Results by group53
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 53
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Pulse Oximetry During the Baseline Visit | Lemborexant Arm | -0.17 | Standard Deviation .94 | percentage of oxygen saturation | |
| Change in Pulse Oximetry During the Baseline Visit | Placebo Arm | -0.33 | Standard Deviation .82 | percentage of oxygen saturation | |
| Change in Pulse Oximetry During Week 1 Visit | Lemborexant Arm | -0.17 | Standard Deviation 1.94 | percentage of oxygen saturation | |
| Change in Pulse Oximetry During Week 1 Visit | Placebo Arm | -0.50 | Standard Deviation 1.05 | percentage of oxygen saturation | |
| Change in Pulse Oximetry During Week 2 Visit | Lemborexant Arm | -0.27 | Standard Deviation 1.49 | percentage of oxygen saturation | |
| Change in Pulse Oximetry During Week 2 Visit | Placebo Arm | -0.20 | Standard Deviation 0.84 | percentage of oxygen saturation | |
| Change in Blood Pressure During Baseline Study Visit | Lemborexant Arm | -9.42 | Standard Deviation 10.40 | mmHg (millimeters of mercury) | |
| Change in Blood Pressure During Baseline Study Visit | Placebo Arm | -2.50 | Standard Deviation 12.29 | mmHg (millimeters of mercury) | |
| Change in Blood Pressure During Week 1 Study Visit | Lemborexant Arm | -6.58 | Standard Deviation 6.64 | mmHg (millimeters of mercury) | |
| Change in Blood Pressure During Week 1 Study Visit | Placebo Arm | -4.50 | Standard Deviation 5.68 | mmHg (millimeters of mercury) | |
| Change in Blood Pressure During Week 2 Study Visit | Lemborexant Arm | 1.09 | Standard Deviation 12.85 | mmHg (millimeters of mercury) | |
| Change in Blood Pressure During Week 2 Study Visit | Placebo Arm | -3.60 | Standard Deviation 8.53 | mmHg (millimeters of mercury) | |
| Change in Patient Consciousness During the Baseline Visit | Lemborexant Arm | -0.17 | Standard Deviation 0.39 | score on a scale | |
| Change in Patient Consciousness During the Baseline Visit | Placebo Arm | 0 | Standard Deviation .63 | score on a scale | |
| Change in Patient Consciousness During the Week 1 Study Visit | Lemborexant Arm | 0.00 | Standard Deviation 0.60 | score on a scale | |
| Change in Patient Consciousness During the Week 1 Study Visit | Placebo Arm | 0.33 | Standard Deviation 0.52 | score on a scale | |
| Change in Patient Consciousness | Lemborexant Arm | -0.18 | Standard Deviation 0.87 | score on a scale | |
| Change in Patient Consciousness | Placebo Arm | -0.20 | Standard Deviation 0.45 | score on a scale | |
| Change in Buprenorphine Plasma Concentration (PK) During the Baseline Visit | Lemborexant Arm | 0.26 | Standard Deviation 0.29 | Nanograms/milliliter (ng/mL) | |
| Change in Buprenorphine Plasma Concentration (PK) During Week 1 Study Visit | Lemborexant Arm | 0.15 | Standard Deviation 0.18 | Nanograms/milliliter (ng/mL) |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04818086/results